- New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE:JNJ) Darzalex for previously untreated patients with multiple myeloma.
- The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Velcade (bortezomib) plus thalidomide and dexamethasone given to patients before a stem cell transplant.
- The regimen's long-term benefits were unclear, NICE said.
- Also, J&J's economic model didn't incorporate Bristol Myers Squibb & Co's (NYSE:BMY) Revlimid (lenalidomide) as maintenance therapy after transplant.
- NICE reviewers noted that maintenance treatment with Revlimid has recently become standard for front-line myeloma post-transplant. J&J's economic model included the costs of Revlimid but not the benefits because no clinical data is available evaluating Revlimid maintenance after Darzalex consolidation therapy.
- NICE has opened the evaluation to comments until September 17 and plans to hold another appraisal committee meeting on November 4 to publish a final decision by January 12, 2022.
- Related content: Benzinga's Full FDA Calendar
- Price Action: JNJ shares are down 0.04% at $172.86 during the premarket session on the last check Monday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
